The Therapeutic Goods Administration (TGA) has officially approved Alyftrek for use in Australia. This follows the recent positive recommendation from the PBAC and brings us closer to Alyftrek being listed on the PBS and accessible to everyone who could benefit.
Alyftrek is a next-generation, once-daily CFTR modulator that targets the underlying cause of CF. It is registered for the treatment of people aged 6 years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical or in vitro evidence.
The registration confirms that eligibility is not limited to people who do not respond or have discontinued Trikafta. For those Australians with a responsive mutation this provides a further treatment option and the potential to benefit from this next-generation triple therapy.
Cystic Fibrosis Australia will keep advocating to ensure Alyftrek is subsidised through the PBS as soon as possible, so it is affordable and accessible to all who need it.
More information here.